Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors
Clinical trial NCT07330076 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07330076
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-06
- Primary completion
- 2030-12-31
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.